Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program

Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients. Sixty-one patients with HCV genotype 1b were enrolled in the Turkish early ac...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hepatology 2017-01, Vol.16 (1), p.71
Main Authors: Köklü, Seyfettin, Köksal, Iftihar, Salih Akarca, Ulus, Balkan, Ayhan, Güner, Rahmet, Demirezen, Aylin, Sahin, Memduh, Akhan, Sila, Ozaras, Reşat, Idilman, Ramazan
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients. Sixty-one patients with HCV genotype 1b were enrolled in the Turkish early access program. Most of the patients were in difficult-to-treat category. Patients were visited at each 4 week throughout the follow-up period. Laboratory findings and adverse events were recorded at each visit. Fifty-seven of 61 enrolled patients completed 24 weeks of treatment. Two patients died as a result of underlying diseases at 12-14th weeks of treatment. Two patients stopped the treatment early as a consequence of virological breakthrough, and 2 patients had viral relapse at the post-treatment follow-up. Overall SVR12 rates were 90% (55/61) and 93.2% (55/59) according to intention-to-treat (ITT) and per protocol (PP) analysis respectively. In ITT analysis, SVR12 was achieved by 93% (13/14) in relapsers, 80% (12/15) in interferon-ineligible patients and 91% (20/22) in previous nonresponder patients. SVR rates were 86.5% and 91.4% in patients with cirrhosis according to ITT and PP analysis respectively. SVR was 95.8% in non-cirrhosis group in both analysis. Patients with previous protease inhibitor experience had an SVR of 87.5%. Common adverse events developed in 28.8% of patients. There were no treatment related severe adverse event or grade-4 laboratory abnormality. Daclatasvir and asunaprevir dual therapy is found to be effective and safe in difficult-to-treat Turkish patients with HCV genotype 1b infection.
ISSN:1665-2681